Pharma: Page 44
-
Sanofi, GSK say dual-acting vaccine prevents COVID-19 from omicron in large trial
A shot the partners have been developing reduced symptomatic infections associated with the variant by 72% compared to a placebo, positioning it as a potential option, if approved, to combat omicron.
By Jonathan Gardner • June 24, 2022 -
Permission granted by Novartis
Novartis to invest $250M in tropical disease drug research
The bulk of the investment will go toward advancing development of three antimalarial drug candidates meant to combat resistance to artemisinin, a common treatment.
By Delilah Alvarado • Updated June 23, 2022 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Pfizer takes stake in Lyme disease partner ahead of key study
Valneva will receive $95 million from Pfizer to support development of a vaccine candidate as the French company’s COVID-19 work sputters.
By Jonathan Gardner • June 21, 2022 -
Stocksy.com/Martí Sans
Sponsored by GoodRxBoost your copay program's visibility before it's too late
Give your copay program the gift of awareness. GoodRx provides a better way to effective programs
June 21, 2022 -
Carol Highsmith. (2005). "The Apex Building" [Photo]. Retrieved from Wikimedia Commons.
Pharma under the microscope as FTC considers new ways to review acquisitions
At a two-day meeting, experts argued drug divestitures may not be enough to prevent market concentration. Economists and regulators also appeared worried by the effect of buyouts on innovation.
By Jonathan Gardner • June 16, 2022 -
National Institute of Allergy and Infectious Diseases. (2017). "Human Respiratory Syncytial Virus" [Micrograph]. Retrieved from Flickr.
GSK claims first positive Phase 3 result for an RSV vaccine
The British drugmaker now plans to seek approval of what could be the first preventive shot for the common lung infection. However, Pfizer, Johnson & Johnson and Moderna are close behind.
By Jonathan Gardner • June 10, 2022 -
Courtesy of Novavax, Australian Broadcasting Corporation
FDA advisers back Novavax's latecomer COVID-19 vaccine
Outside experts debated the shot's safety profile and its efficacy versus the omicron variant but ultimately supported the vaccine, which is made using more traditional technology than Pfizer's and Moderna's.
By Jonathan Gardner • Updated June 7, 2022 -
Getty Images
Roche keeps the faith in new cancer immunotherapy despite trial setbacks
An ambitious development plan has so far resulted in two late-stage disappointments, but the Swiss drugmaker remains confident there's more to come from its combination treatment.
By Jonathan Gardner • June 7, 2022 -
Getty Images
Sponsored by CorEvitasConverging data sets holds promise for creating holistic view of patient lived experience
Real-world data (RWD) and real-world evidence (RWE) are coming into increasingly widespread use across the entire pharmaceutical product development lifecycle.
June 6, 2022 -
Permission granted by Bristol-Myers Squibb
Bristol Myers bets $4B on Turning Point and its targeted cancer drugs
While priced at a significant premium, the deal values Turning Point well below its peak valuation last year, a potential sign biotechs might be adjusting their expectations amid the sector's downturn.
By Jonathan Gardner • Updated June 3, 2022 -
Courtesy of Regeneron Pharmaceuticals
Regeneron buys control of cancer drug Libtayo from Sanofi
The biotech, which has been partnered with Sanofi for years, will pay $900 million upfront to gain sole control of the cancer immunotherapy.
By Jonathan Gardner • Updated June 2, 2022 -
Permission granted by Bristol-Myers Squibb
Bristol Myers' autoimmune drug shows potential in lupus
Positive Phase 2 results could help boost company executives' arguments that the drug, called deucravacitinib and under FDA review in psoriasis, will become a top-seller.
By Jonathan Gardner • June 1, 2022 -
Warren Little via Getty Images
Pfizer to exit GSK consumer health joint venture after spinoff
The pharma currently holds a 32% stake in the business, which is set to become a standalone company that will trade on the London Stock Exchange beginning in July.
By Kristin Jensen • June 1, 2022 -
Roche SMA drug approved in youngest infants, challenging Novartis and Biogen
Evrysdi, the only oral drug for the neurodegenerative disorder, can now be used to treat babies younger than 2 months who have been identified through newborn screening.
By Jonathan Gardner • May 31, 2022 -
Erik S. Lesser via Getty Images
Merck study results signal blood cancer potential for new type of immunotherapy
Bristol Myers beat Merck to the first approval of a so-called LAG-3 inhibitor. But Merck is advancing its own and data to be presented at ASCO show it could help treat Hodgkin's lymphoma.
By Jonathan Gardner • May 26, 2022 -
Courtesy of Eli Lilly
Lilly to expand, add jobs with two new factories in Indiana
The drugmaker is spending $2 billion on the new facilities, which will be staffed with up to 500 new corporate positions and support production of its pipeline of new products.
By Kristin Jensen • May 26, 2022 -
Pfizer pledges not-for-profit sale of medicines in low-income countries
The pharma has been criticized for not doing enough to make its COVID-19 vaccine and pill available globally. The new initiative commits Pfizer to supplying current and future branded medicines at lower cost to 45 countries.
By Jonathan Gardner • May 25, 2022 -
Jeenah Moon via Getty Images
Pfizer, Lilly bolster cases for experimental ulcerative colitis drugs
The two companies are each developing new types of medicines that they hope can soon win FDA approval for treating the autoimmune disease.
By Ned Pagliarulo • May 24, 2022 -
Courtesy of Pfizer
Pfizer says 3 doses of its COVID-19 vaccine works in youngest children
The drugmaker, along with partner BioNTech, plans to submit the new data to the FDA this week. The agency has scheduled a meeting for outside experts to review the data in mid-June.
By Jonathan Gardner • May 23, 2022 -
Getty Images
Sponsored by GoodRxCommon barriers to patient engagement: What's your strategy?
As with treatment, and even adherence, there is no 'one size fits all' when it comes to patient engagement.
May 23, 2022 -
Bayer backs out of Atara cell therapy deal
The German drugmaker will hand back rights to two CAR-T cell therapies it was developing with Atara, which said it would reassess its strategy for the programs.
By Ned Pagliarulo • May 20, 2022 -
AbbVie asks FDA to approve Parkinson’s treatment
The company believes the treatment, which uses prodrug versions of two commonly used Parkinson's medications, could be a longer-lasting option for patients and blockbuster product for AbbVie.
By Jacob Bell • May 20, 2022 -
Permission granted by Bristol-Myers Squibb
Bristol Myers' Opdivo comes up short in bladder cancer trial
The top-selling immunotherapy failed to improve survival in first-line urothelial carcinoma, a tumor type that's proved difficult to treat with drugs like Opdivo.
By Ned Pagliarulo • May 16, 2022 -
Permission granted by Vetter Pharma
Sponsored by Vetter PharmaMaking sub-visible particles visible
Sub-visible particles can lower the effectiveness of a drug, which is why regulatory authorities are demanding processes be developed, validated and set up in such a way as to minimize all forms of contamination.
By Dr. Melanie Zerulla-Wernitz, Head of the Analytical Science Laboratory, Vetter Pharma • May 16, 2022 -
Courtesy of Eli Lilly
Lilly wins FDA approval for new kind of diabetes drug
Tirzepatide, now branded as Mounjaro, helped improve blood sugar control in testing and was shown to have powerful weight loss effects as well, making it one of the most closely watched drugs in Lilly's pipeline.
By Jonathan Gardner • Updated May 16, 2022
Previous
